HANALL BIOPHARMA CO., LTD.

Other languages Hanall Biopharma Co., Ltd.

Equities

A009420

KR7009420001

End-of-day quote Korea S.E. Other stock markets 23:00:00 23/05/2024 BST			5-day change	1st Jan Change
35,800 ^KRW	-1.10%		-4.02%	-19.19%

05-03	HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease	CI
03-06	Hanall Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease	05-03
Hanall Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-06
Hanall Biopharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab	11/10/22
Hanall's Second FcRn Inhibitor HL161ANS to Be Added to the Development Program of Its Licensed Partner	04/10/22
Hanall Biopharma Co.,Ltd announces an Equity Buyback for 543,479 shares.	10/03/22
Hanall Biopharma Co.,Ltd authorizes a Buyback Plan.	09/03/22
Hanall Biopharma Co.,Ltd Announces Consolidated Earnings Results for the Second Quarter and Six Months of 2021	29/07/21
Hanall Biopharma Co.,Ltd Announces Earnings Results for the First Quarter Ended March 31, 2021	06/05/21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer